MedPath

Ceftriaxone

Generic Name
Ceftriaxone
Brand Names
Rocephin
Drug Type
Small Molecule
Chemical Formula
C18H18N8O7S3
CAS Number
73384-59-5
Unique Ingredient Identifier
75J73V1629

Overview

Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.

Background

Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.

Indication

Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.

Associated Conditions

  • Abscess Brain
  • Bacterial Endocarditis
  • Bacterial Infections
  • Bacterial Sinusitis
  • Bone and Joint Infections
  • Chancroid
  • Community Acquired Pneumonia (CAP)
  • Conjunctivitis gonococcal neonatal
  • Epididymitis
  • Epiglottitis
  • Gonococcal arthritis
  • Gonococcal infection of pharynx
  • Gonococcal pelvic inflammatory disease
  • Intraabdominal Infections
  • Lower respiratory tract infection bacterial
  • Lyme Neuroborreliosis
  • Meningitis, Bacterial
  • Ophthalmia neonatorum due to gonococcus
  • Postoperative Infections
  • Prosthetic Joint Infections
  • Sepsis Bacterial
  • Septic Arthritis
  • Shigellosis
  • Skin and Subcutaneous Tissue Bacterial Infections
  • Syphilis
  • Vulvovaginitis gonococcal
  • Whipple Disease
  • Bacterial otitis media
  • Complicated Urinary Tract Infection caused by susceptible bacteria
  • Disease caused by Salmonella typhi
  • Susceptible Bacterial Infections
  • Uncomplicated Gonorrhea
  • Uncomplicated Urinary tract infection bacterial

FDA Approved Products

Ceftriaxone Sodium
Manufacturer:A-S Medication Solutions
Route:INTRAVENOUS, INTRAMUSCULAR
Strength:1 g in 1 1
Approved: 2020/03/05
NDC:50090-3810
Ceftriaxone Sodium
Manufacturer:Hospira, Inc
Route:INTRAVENOUS, INTRAMUSCULAR
Strength:2 g in 1 1
Approved: 2017/06/15
NDC:0409-7335
Ceftriaxone Sodium
Manufacturer:A-S Medication Solutions
Route:INTRAMUSCULAR, INTRAVENOUS
Strength:250 mg in 1 1
Approved: 2022/03/22
NDC:50090-4689
Ampicillin and Sulbactam
Manufacturer:WG Critical Care, LLC
Route:INTRAVENOUS, INTRAMUSCULAR
Strength:0.5 g in 10 mL
Approved: 2023/02/23
NDC:44567-210
CEFTRIAXONE
Manufacturer:A-S Medication Solutions
Route:INTRAMUSCULAR, INTRAVENOUS
Strength:1 g in 1 1
Approved: 2020/12/24
NDC:50090-0945

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath